GlassScriptPhysician profile
David R Huston
NPI 1215967823
$4,637.93
in general payments reported to CMS, 2019-2025
25 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $535 · 2023: $789 · 2024: $2,066 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Travel and Lodging: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.53 |
| Travel and Lodging | $985.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,604.61 | 2023-2025 | Wavewriter Alpha Prime 16, General - Therapies, Na |
| Abbott Laboratories | $518.04 | 2021-2025 | Proclaim, Eterna |
| Nevro Corp. | $485.27 | 2022-2024 | Senza |
| Collegium Pharmaceutical, INC. | $460.79 | 2023-2025 | Belbuca, Xtampza, Nucynta |
| Globus Medical, INC. | $405.32 | 2025 | Senza |
| Abbvie INC. | $288.93 | 2022-2025 | |
| Stryker Corporation | $126.15 | 2025 | Optablate |
| Relievant Medsystems, INC. | $111.46 | 2023 | Intracept |
| Vertex Pharmaceuticals Incorporated | $96.66 | 2025 | |
| Pfizer INC. | $72.67 | 2021 | |
| Scilex Pharmaceuticals INC. | $64.38 | 2022-2024 | Ztlido |
| Impel Pharmaceuticals LLC | $46.76 | 2025 | Trudhesa |
| Bioventus LLC | $45.90 | 2023 | Durolane |
| Lundbeck LLC | $43.92 | 2022-2023 | Vyepti |
| Nalu Medical, INC. | $43.11 | 2024-2025 | Nalu Neurostimulation System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $33.65 | 2023 | Lyvispah |
| Kowa Pharmaceuticals America, INC. | $32.36 | 2023 | Seglentis |
| Lilly USA, LLC | $27.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.42 | 2022 | |
| Innovation Technologies INC | $19.37 | 2022 | |
| Medtronic, INC. | $17.62 | 2025 | Inceptiv |
| Azurity Pharmaceuticals, INC. | $16.18 | 2023 | Horizant |
| Forte Bio-Pharma LLC | $14.74 | 2024 | Prolate, Nalocet |
| Biohaven Pharmaceutical Holding Company LTD. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Huston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.